27 May 2019 --- Regulatory confusion over cannabinoids (CBD) has opened up the space for alternatives, within which Gencor has released Levagen, a palmitoylethanolamide (PEA) ingredient touted as having anti-inflammatory and pain relief properties. The company also utilizes a novel delivery method coined LipiSperse that increases the bioavailability of its PEA ingredient and allows for applications such as shots and chews. “This opens up the market and allows consumers to be more familiar with PEA. It can add value to products within the sports nutrition space,” Mariko Hill, Product Development Executive at Gencor tells NutritionInsight, at Vitafoods, Geneva, earlier this month.
